Advancing Screening Protocols: Investigating the Role of Alpha-Fetoprotein Supported by Turkish Ministry of Health Data in Hepatocellular Carcinoma and Germ Cell Tumors
Objectives: This study aimed to deepen our understanding of AFP's role in disease, evaluate its current use as a screening tool for HCC and germ cell tumors, and explore potential improvements in screening protocols to enhance early detection and improve patient outcomes.
Methods: The study analyzed the data of AFP test requests between 2017-2021, comprising a total of 15.618.083 tests from 3,213,258 individuals. The AFP levels were determined using the immunoassay method and the results were transferred to the National Health Database, which is referred to as e-pulse by the Ministry of Health. This database encompasses the health records of patients who have sought medical services from all healthcare institutions in Turkey, including their demographic characteristics, laboratory data, medication usage, comorbidities, and other health-related records.
Results: The results showed that the average number of tests per person was 4.86, and the number of tests per 100,000 population was 18,899. While the number of AFP tests increased in the earlier years, a noticeable decrease was observed in 2020 and 2021. Comparing genders, the test was more frequently requested for women, with a ratio of 1.46- 1.61 for female/male test numbers across the years. AFP testing was most common in the 18-64 age group, followed by patients over 65, while the 0-17 age group had the least number of tests. The study also examined the effectiveness of AFP as a screening tool for HCC. It was found that AFP alone had limitations as a screening test, as its sensitivity varied between 58% and 80%.
Conclusion: In conclusion, this study sheds light on the role of AFP as a tumor marker in HCC and germ cell tumors. Although it has limitations as a standalone screening tool, AFP testing, in combination with other diagnostic methods, contributes to the early detection and monitoring of HCC.
1. Stewart Sell, alpha-fetoprotein (afp), stem cells, and cancer: how study of the production of afp during chemical hepatocarcinogenesis led to reaffirmation of the stem cell theory of cancer. Tumour Biol. 2008 ; 29(3): 161–180.
2. Szutowicz A., Raszeja-Specht A., editors. Diagnostyka Laboratoryjna. Gdański Uniwersytet Medyczny; Gdańsk, Poland: 2011. Diagnostyka laboratoryjna; pp. 107–126
3. El-Bahrawy M. Alpha-fetoprotein-producing non-germ cell tumours of the female genital tract. Eur J Cancer 2010; 46:1317.
4. Yuan L, Xu ZY, Ruan SM, Mo S, Qin JJ, Cheng XD. Long noncoding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance. Mol Cancer. 2020 May 27;19(1):96.
5. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A. et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer J Clinicians. 2021; 71: 209-249
6. Zhang X., El-Serag H.B., Thrift A.P. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes & Control. 2021; 32: 317-325
7. Marrero J.A., Kulik L.M., Sirlin C.B., Zhu A.X., Finn R.S., Abecassis M.M.et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases.Hepatology. 2018; 68: 723-750
8. Tzartzeva K., Obi J., Rich N.E., Parikh N.D., Marrero J.A., Yopp A. et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018; 154: 1706-1718. e1701
9. Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American Society of Clinical Oncology . American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors.
10. Kanwal F, Kramer JR, Duan Z, Yu X, White D, El-Serag HB. Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. Clin Gastroenterol Hepatol. 2016 Feb;14(2):301-8.e1-2.
11. Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography - a randomised study. Aliment Pharmacol Ther. 2013 Aug;38(3):303-12.
12. Wang M, Devarajan K, Singal AG, Marrero JA, Dai J, Feng Z. Et al. The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma. Cancer Prev Res (Phila). 2016 Feb;9(2):172-9.
13. Kulik L, & El-Serag HB (2019). Epidemiology and management of hepatocellular carcinoma. Gastroenterology, 156(2), 477– 491.e471.
14. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu and European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
15. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma
16. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. HALT-CTrialGroup. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.
17. Turshudzhyan A, Wu GY. Persistently Rising Alpha-fetoprotein in the Diagnosis of Hepatocellular Carcinoma: A Review. J Clin Transl Hepatol. 2022 Feb 28;10(1):159-163.